Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Malin's average Accounts Receivable for the
six
months ended in Dec. 2024 was $0.00 Mil. Malin's Revenue for the
six
months ended in Dec. 2024 was $0.00 Mil.
The historical rank and industry rank for Malin's Days Sales Outstanding or its related term are showing as below:
MLLNF's Days Sales Outstanding is not ranked *
in the Drug Manufacturers industry.
Industry Median: 71.98 * Ranked among companies with meaningful Days Sales Outstanding only.
Malin's Days Sales Outstanding
stayed the same
from Dec. 2023 (0.00) to Dec. 2024 (0.00).
Malin (OTCPK:MLLNF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Malin Days Sales Outstanding Related Terms
Malin Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Malin's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLNF vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Malin's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malin Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Malin's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Malin's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malin (MLLNF) has a Days Sales Outstanding of 0.00 as of Dec. 2024. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Malin and its competitors.
Is Malin's Days Sales Outstanding too high?
Malin's current Days Sales Outstanding is 0.00. Overall, Malin has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Malin's Days Sales Outstanding compare to ZTS and UTHR?
Malin's Days Sales Outstanding of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Days Sales Outstanding is 71.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Malin and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malin's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (MLLNF) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Malin's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Malin (MLLNF), the current Days Sales Outstanding is 0.00 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.
17GF Score
Get the complete analysis for MLLNF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLNF has been successfully added to your 
